Allegro Ophthalmics to Present for the First Time the Results of Its Phase 2 Risuteganib Intermediate Dry Age-Related Macular Degeneration Study at the ASRS Annual Meeting 2019
SAN JUAN CAPISTRANO, Calif.--(BUSINESS WIRE)--<a href="https://twitter.com/hashtag/DME?src=hash" target="_blank">#DME</a>--Allegro Ophthalmics announced that the results of its US Phase 2 study evaluating risuteganib for intermediate dry AMD will be presented at ASRS 2019.